In practice, this means we should think beyond weight/body-mass index alone and focus on outcomes that matter clinically: cardiovascular risk, body composition, function, symptoms, and long-term sustainability of response
Results take longer to appear but compliance is significantly higher because people do not quit from unbearable side effects
It is not intended for human or animal administration, and must not be used for diagnostic, therapeutic, or clinical applications
This creates negative pressure inside the barrel
Further dual-agonist and even triple-agonist incretin drugs are in development
About 60% of GLP-1 users who experience gastrointestinal side effects report that nighttime injection significantly reduces their perception of nausea, simply because they sleep through the worst of it